Blueprint Medicines Corp (NAS:BPMC)
$ 95.39 0.82 (0.87%) Market Cap: 6.01 Bil Enterprise Value: 5.83 Bil PE Ratio: 0 PB Ratio: 19.46 GF Score: 81/100

Blueprint Medicines Corporate call Transcript

Aug 17, 2022 / 12:00PM GMT
Release Date Price: $61.17 (-10.77%)
Operator

Good morning. My name is Melissa, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint Medicines Conference Call to discuss the PIONEER Part 2 Top-line Results.

(Operator Instructions)

Jenna Cohen, you may now begin your conference.

Jenna Cohen
Blueprint Medicines Corporation - Senior Director & Head of IR

Thank you, Melissa. Good morning, everyone, and welcome. Earlier this morning, we issued a press release with highlights from the positive PIONEER Part 2 top line results for AYVAKIT in non-advanced systemic mastocytosis. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.

Joining me on today's call are Kate Haviland, Chief Executive Officer; Dr. Becker Hewes, Chief Medical Officer; and Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women's Hospital. Also

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot